Your browser doesn't support javascript.
loading
Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab.
Berger, Raanan; Dinstag, Gal; Tirosh, Omer; Schiff, Eyal; Kleiner, David; Aldape, Kenneth D; Ruppin, Eytan; Beker, Tuvik; Kurzrock, Razelle.
Afiliação
  • Berger R; Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel tuvik@pangeabiomed.com rkurzrock@mcw.edu raanan.berger@sheba.health.gov.il.
  • Dinstag G; Pangea Biomed, Tel Aviv, Israel.
  • Tirosh O; Pangea Biomed, Tel Aviv, Israel.
  • Schiff E; Pangea Biomed, Tel Aviv, Israel.
  • Kleiner D; Laboratory of Pathology, Center for Cancer Research, NCI, Bethesda, Maryland, USA.
  • Aldape KD; Laboratory of Pathology, Center for Cancer Research, NCI, Bethesda, Maryland, USA.
  • Ruppin E; Cancer Data Science Lab, Center for Cancer Research, NCI, Bethesda, Maryland, USA.
  • Beker T; Pangea Biomed, Tel Aviv, Israel tuvik@pangeabiomed.com rkurzrock@mcw.edu raanan.berger@sheba.health.gov.il.
  • Kurzrock R; Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA tuvik@pangeabiomed.com rkurzrock@mcw.edu raanan.berger@sheba.health.gov.il.
J Immunother Cancer ; 10(12)2022 12.
Article em En | MEDLINE | ID: mdl-36600603

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Nivolumabe Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Nivolumabe Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article